Ruxolitinib for essential thrombocythemia?

Ruxolitinib for essential thrombocythemia?

Essential thrombocythemia

Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000. The median age at diagnosis is 65 to 70 years, but the disease may occur at any age. The female to male ratio is about 2:1. The clinical pictu...

Emerging treatments for essential thrombocythemia

In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe a disorder characterized by permanent elevation of a platelet count to more than three times normal, hyperplasia of megakaryocytes, and the tendency for venous thrombosis and spontaneous hemorrhage. Over the last 75 years, and particularly in the past 6 years, major progress has been made in our understanding of e...

Thrombospondin in essential thrombocythemia.

Essential thrombocythemia is a myeloproliferative disorder characterized by frequent bleeding and thrombotic complications. On a molecular level, two abnormalities of platelet thrombospondin have been identified: abnormal glycosylation of the intact 185,000-dalton chain has been detected and a shortened form of the thrombospondin chain is present. We have used two monoclonal antibodies and Lens...

Essential thrombocythemia and pregnancy.

+39.79.228375. Fax. international +39.79.228282. Received January 17, 1995; accepted February 27, 1995. Sir, the management of essential thrombocythemia (ET) in young patients is still controversial and represents an intriguing problem especially, during pregnancy. We have read with interest the article by Radaelli et al., which reports a concise review of published data on the course of pregna...